# Oklo Inc.: financial statements, quarterly

OKLO · NYSE · CIK 1849056 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oklo.md) · [Financials](/companies/oklo/financials.md) · [Filings](/companies/oklo/filings.md) · [Insiders](/companies/oklo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oklo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-054571.md) | not reported | not reported | not reported | [1.2](/filings/0001628280-26-054571.md) |
| Research and development | $m | [1.7](/filings/0001628280-24-047875.md) | [4.3 d](/filings/0001628280-25-014490.md) | [3.7](/filings/0001628280-25-025166.md) | [10.7](/filings/0001628280-25-039571.md) | [5.1](/filings/0001628280-25-051349.md) | [7.3 d](/filings/0001628280-26-018698.md) | [7.8](/filings/0001849056-26-000037.md) | [11.5](/filings/0001628280-26-054571.md) | [14.9](/filings/0001628280-25-051349.md) | [24.6 d](/filings/0001628280-26-018698.md) | [27.0](/filings/0001849056-26-000037.md) | [39.5](/filings/0001628280-26-054571.md) |
| Operating income | $m | [(4.7)](/filings/0001628280-24-047875.md) | [(7.3) d](/filings/0001628280-25-014490.md) | [(7.4)](/filings/0001628280-25-025166.md) | [(17.8)](/filings/0001628280-25-039571.md) | [(12.3)](/filings/0001628280-25-051349.md) | [(15.4) d](/filings/0001628280-26-018698.md) | [(17.9)](/filings/0001849056-26-000037.md) | [(28.0)](/filings/0001628280-26-054571.md) | [(36.3)](/filings/0001628280-25-051349.md) | [(57.1) d](/filings/0001628280-26-018698.md) | [(51.2)](/filings/0001849056-26-000037.md) | [(73.2)](/filings/0001628280-26-054571.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-047875.md) | [0.0 d](/filings/0001628280-25-014490.md) | [0.0](/filings/0001628280-25-025166.md) | [0.2](/filings/0001628280-25-039571.md) | [0.2](/filings/0001628280-25-051349.md) | [0.3 d](/filings/0001628280-26-018698.md) | [(4.4)](/filings/0001849056-26-000037.md) | [0.4](/filings/0001628280-26-054571.md) | [0.5](/filings/0001628280-25-051349.md) | [(1.1) d](/filings/0001628280-26-018698.md) | [3.2](/filings/0001849056-26-000037.md) | [(3.2)](/filings/0001628280-26-054571.md) |
| Net income | $m | [(8.7)](/filings/0001628280-24-047875.md) | [(14.3) d](/filings/0001628280-25-014490.md) | [(24.0)](/filings/0001628280-25-039571.md) | [(27.3)](/filings/0001628280-25-039571.md) | [(10.0)](/filings/0001628280-25-051349.md) | [(12.3) d](/filings/0001628280-26-018698.md) | [(9.8)](/filings/0001628280-26-054571.md) | [(24.7)](/filings/0001628280-26-054571.md) | [(29.7)](/filings/0001628280-25-051349.md) | [(41.4) d](/filings/0001628280-26-018698.md) | [(33.1)](/filings/0001628280-26-054571.md) | [(48.5)](/filings/0001628280-26-054571.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001628280-24-047875.md) | not reported | [(0.34)](/filings/0001628280-25-025166.md) | [(0.27)](/filings/0001628280-25-039571.md) | [(0.08)](/filings/0001628280-25-051349.md) | not reported | [(0.07)](/filings/0001849056-26-000037.md) | [(0.18)](/filings/0001628280-26-054571.md) | [(0.20)](/filings/0001628280-25-051349.md) | not reported | [(0.19)](/filings/0001849056-26-000037.md) | [(0.28)](/filings/0001628280-26-054571.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001628280-24-047875.md) | not reported | [(0.34)](/filings/0001628280-25-025166.md) | [(0.27)](/filings/0001628280-25-039571.md) | [(0.08)](/filings/0001628280-25-051349.md) | not reported | [(0.07)](/filings/0001849056-26-000037.md) | [(0.18)](/filings/0001628280-26-054571.md) | [(0.20)](/filings/0001628280-25-051349.md) | not reported | [(0.19)](/filings/0001849056-26-000037.md) | [(0.28)](/filings/0001628280-26-054571.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.7](/filings/0001410578-23-002506.md) | [9.9](/filings/0001628280-25-014490.md) | [0.4](/filings/0001410578-24-000635.md) | [106](/filings/0001410578-24-001386.md) | [91.8](/filings/0001628280-24-047875.md) | [97.1](/filings/0001628280-26-018698.md) | [90.1](/filings/0001628280-25-025166.md) | [227](/filings/0001628280-26-054571.md) | [410](/filings/0001628280-25-051349.md) | [788](/filings/0001628280-26-054571.md) | [1,594](/filings/0001849056-26-000037.md) | [1,645](/filings/0001628280-26-054571.md) |
| Current assets | $m | [1.8](/filings/0001410578-23-002506.md) | [14.2](/filings/0001628280-25-014490.md) | [0.7](/filings/0001410578-24-000635.md) | [239](/filings/0001410578-24-001386.md) | [235](/filings/0001628280-24-047875.md) | [232](/filings/0001628280-26-018698.md) | [205](/filings/0001628280-25-025166.md) | [543](/filings/0001628280-25-039571.md) | [932](/filings/0001628280-25-051349.md) | [1,254](/filings/0001628280-26-054571.md) | [2,226](/filings/0001849056-26-000037.md) | [2,521](/filings/0001628280-26-054571.md) |
| Total assets | $m | [520](/filings/0001410578-23-002506.md) | [14.9](/filings/0001628280-25-014490.md) | [308](/filings/0001410578-24-000635.md) | [299](/filings/0001410578-24-001386.md) | [294](/filings/0001628280-24-047875.md) | [282](/filings/0001628280-26-018698.md) | [302](/filings/0001628280-25-025166.md) | [731](/filings/0001628280-25-039571.md) | [1,246](/filings/0001628280-25-051349.md) | [1,528](/filings/0001628280-26-054571.md) | [2,704](/filings/0001849056-26-000037.md) | [3,358](/filings/0001628280-26-054571.md) |
| Current liabilities | $m | [2.4](/filings/0001410578-23-002506.md) | [3.2](/filings/0001628280-25-014490.md) | [4.6](/filings/0001410578-24-000635.md) | [4.9](/filings/0001410578-24-001386.md) | [4.8](/filings/0001628280-24-047875.md) | [5.3](/filings/0001628280-26-018698.md) | [5.7](/filings/0001628280-25-025166.md) | [7.6](/filings/0001628280-25-039571.md) | [13.8](/filings/0001628280-25-051349.md) | [25.5](/filings/0001628280-26-054571.md) | [37.1](/filings/0001849056-26-000037.md) | [52.0](/filings/0001628280-26-054571.md) |
| Total liabilities | $m | [20.0](/filings/0001410578-23-002506.md) | [49.2](/filings/0001628280-25-014490.md) | [11.6](/filings/0001410578-24-000635.md) | [29.9](/filings/0001410578-24-001386.md) | [30.5](/filings/0001628280-24-047875.md) | [30.9](/filings/0001628280-26-018698.md) | [32.8](/filings/0001628280-25-025166.md) | [34.7](/filings/0001628280-25-039571.md) | [40.6](/filings/0001628280-25-051349.md) | [52.2](/filings/0001628280-26-054571.md) | [64.9](/filings/0001849056-26-000037.md) | [84.3](/filings/0001628280-26-054571.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-054571.md) | not reported | [0.7](/filings/0001628280-26-054571.md) |
| Shareholders' equity | $m | [(20.7)](/filings/0001628280-24-047875.md) | [(34.4)](/filings/0001628280-26-018698.md) | [(57.3)](/filings/0001628280-25-039571.md) | [269](/filings/0001628280-25-051349.md) | [263](/filings/0001628280-25-051349.md) | [251](/filings/0001628280-26-054571.md) | [269](/filings/0001628280-26-054571.md) | [696](/filings/0001628280-26-054571.md) | [1,206](/filings/0001628280-25-051349.md) | [1,476](/filings/0001628280-26-054571.md) | [2,639](/filings/0001628280-26-054571.md) | [3,274](/filings/0001628280-26-054571.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.6) d](/filings/0001628280-24-047875.md) | [(5.6) d](/filings/0001628280-25-014490.md) | [(7.3)](/filings/0001628280-25-025166.md) | [(9.8) d](/filings/0001628280-25-039571.md) | [(7.9) d](/filings/0001628280-25-051349.md) | [(13.5) d](/filings/0001628280-26-018698.md) | [(12.2)](/filings/0001849056-26-000037.md) | [(18.5) d](/filings/0001628280-26-054571.md) | [(18.0) d](/filings/0001628280-25-051349.md) | [(33.4) d](/filings/0001628280-26-018698.md) | [(17.9)](/filings/0001849056-26-000037.md) | [(47.6) d](/filings/0001628280-26-054571.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-047875.md) | [0.0 d](/filings/0001628280-25-014490.md) | [0.1](/filings/0001628280-25-025166.md) | [0.1 d](/filings/0001628280-25-039571.md) | [0.1 d](/filings/0001628280-25-051349.md) | [0.1 d](/filings/0001628280-26-018698.md) | [0.3](/filings/0001849056-26-000037.md) | [0.9 d](/filings/0001628280-26-054571.md) | [5.0 d](/filings/0001628280-25-051349.md) | [27.0 d](/filings/0001628280-26-018698.md) | [32.8](/filings/0001849056-26-000037.md) | [94.1 d](/filings/0001628280-26-054571.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [68.8](/filings/0001410578-24-001386.md) | [68.5](/filings/0001628280-24-047875.md) | [70.3](/filings/0001628280-25-025166.md) | [100](/filings/0001628280-25-039571.md) | [122](/filings/0001628280-25-051349.md) | [138](/filings/0001849056-26-000037.md) | [140](/filings/0001628280-26-054571.md) | [150](/filings/0001628280-25-051349.md) | [170](/filings/0001849056-26-000037.md) | [176](/filings/0001628280-26-054571.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 186,017,650 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001628280-26-054571.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.